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Predictors of cardiovascular events in patients with type 2 dia-
betic nephropathy and hypertension: A case for albuminuria.
Individuals with type 2 diabetes and nephropathy represent
a particularly high-risk group for both adverse cardiac as well
as renal events. Using the Irbesartan in Diabetic Nephropathy
Trial (IDNT) cohort, our objective was to determine baseline
characteristics of individuals with type 2 diabetic nephropathy
and hypertension predictive for cardiac events.
IDNT identified 1715 individuals with type 2 diabetic
nephropathy and hypertension having serum creatinine of 1.0
to 3.0 mg/dL and urinary albumin excretion rates ≥900 mg/day.
A cardiovascular (CV) composite was used consisting of CV
death, nonfatal MI, hospitalization for heart failure, stroke, am-
putation, and coronary and peripheral revascularization. Using
multivariable Cox regression analysis, 41 baseline characteris-
tics determined a priori were analyzed for their potential rela-
tionship to risk of experiencing a CV event.
Of the 1715 individuals, 518 (30.2%) had at least one of the
CV composite end points. Older age, male gender, longer du-
ration of diabetes, history of cardiovascular disease, history of
CHF, high urinary albumin:creatinine ratio, and low serum al-
bumin were strong predictors for CV events; of these, prior
history of CVD (RR 2.00, 95% CI 1.63–2.45; P < 0.0001) and
high urinary albumin:creatinine ratio (RR 1.29 per natural log
unit, 95% CI 1.13–1.48; P = 0.0002) at baseline were highly
predictive for cardiovascular events.
In conclusion, among individuals with hypertension and di-
abetic nephropathy, both the degree of albuminuria and lower
serum albumin levels provide additional prognostic informa-
tion concerning cardiovascular risk, in addition to traditional
coronary risk factors.
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There is increasing awareness of the cardiorenal axis
in cardiovascular disease (CVD), with impaired and pro-
gressive loss of renal function being considered a signifi-
cant and potent factor augmenting CVD [1, 2]. Paralleling
the increasing prevalence of type 2 diabetes in the gen-
eral population, there has been a significant and dramatic
increase in the number of patients with type 2 diabetic
nephropathy [3]. Individuals having diabetic nephropa-
thy represent a particularly high-risk group for both ad-
verse cardiac and renal events [4].
Patients with diabetic nephropathy frequently have
one or more conventional coronary risk factors, but this
alone may not be sufficient to account for their predispo-
sition for cardiovascular disease [5, 6]. These individuals
may possess other nonconventional factors in addition
to traditional coronary factors, which also heighten their
cardiovascular risk. What these factors are, and their rel-
ative predictive value for cardiovascular (CV) events in
patients with hypertension and diabetic nephropathy, is
less clear. Identifying variables predictive of cardiovascu-
lar events among this high-risk cohort may provide more
insight to factors promoting disease progression.
The Irbesartan in Diabetic Nephropathy Trial (IDNT)
examined the clinical effectiveness of blood pressure con-
trol based on irbesartan, amlodipine, or placebo against a
background of other antihypertensive therapies in reduc-
ing the progression of renal disease in 1715 diabetic pa-
tients with established nephropathy [7]. Using the IDNT
cohort, our objective was to determine baseline charac-
teristics of individuals with type 2 diabetic nephropathy
and hypertension that associate with an increased risk for
cardiovascular events.
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METHODS
Patients
The IDNT was an investigator-initiated, prospective,
three-arm, randomized, double-blinded study of patients
with diabetic nephropathy and hypertension to deter-
mine the relative efficacy of antihypertensive treatment
based on irbesartan or amlodipine or placebo plus other
antihypertensive agents. A description of the protocol
and details of the baseline characteristics and clinical
outcomes of this study have been previously published
[7]. In addition to coded medication, all patients also
received open-label hypertensive treatment, excluding
angiotensin-converting enzyme inhibitors (ACEi), an-
giotensin receptor blockers (ARBs), or calcium channel
blockers (CCBs) as needed to reduce blood pressure [7].
Briefly, the inclusion criteria were patients aged between
30 to 70 years having type 2 diabetes mellitus compli-
cated by overt nephropathy (24-hour protein excretion
rate ≥900 mg/day), serum creatinine between 1.0 and
3.0 mg/dL if female, or between 1.2 and 3.0 mg/dL if male,
and either baseline seated blood pressures >135/85 mm
Hg or having presented receiving medication for hyper-
tension [7]. Exclusion criteria included the presence of
a kidney disease other than diabetic nephropathy, abso-
lute requirement for systemic immunosuppressive ther-
apy, or a serum potassium concentration outside the nor-
mal range [7].
Treatment
Eligible patients were randomly assigned in a 1:1:1
fashion to treatment with irbesartan 300 mg/day, am-
lodipine 10 mg/day, or matched placebo.
Outcomes
The primary outcome of the main trial was time to the
composite of doubling of baseline serum creatinine con-
centration, end-stage renal disease (defined as a serum
creatinine ≥6 mg/dL, renal dialysis, or transplantation),
or all-cause mortality [7]. A prespecified CV outcome
was the composite of cardiovascular death, nonfatal my-
ocardial infarction (MI), heart failure (HF) resulting in
hospitalization, stroke, unplanned coronary revascular-
ization procedures, unplanned peripheral revasculariza-
tion, and/or below knee amputation [7]; this CV com-
posite was used to evaluate risk for experiencing a CV
event. CV events were not ascertained after end-stage
renal disease was reached.
Statistical analysis
The cardiovascular composite end point was used as
the dependent outcome variable. As a marker of renal
function, eGFR using the four-component Modification
of Diet in Renal Disease (MDRD) formula was used,
defined as: 186 × (serum creatinine in mg/dL)−1.154 ×
(age in years)−0.203; for women and non-Caucasians, the
product was multiplied by a correction factor of 0.742 and
1.21, respectively [8].
Analysis for CV predictors. All patients were followed
for the cardiovascular composite (time to first event) until
either end-stage renal disease was reached or they were
lost to follow-up. Forty-one potential predictors (listed
in the Appendix) were identified a priori among the de-
mographic, history, and laboratory variables. Univariate
analyses were performed using proportional hazards re-
gression models (Cox regressions) for each of the 41
candidate predictors. To assess the roles of the various
candidate predictors further, analysis was performed with
multivariable Cox models allowing all 41 potential pre-
dictors to compete for entry. A stepwise procedure was
used in which variables were added or removed from
the model, depending on whether their contribution to
the model was statistically significant, and on the rela-
tive degree of significance. A final multivariable model
was evolved, all of whose terms contributed to the most
parsimonious set of predictive variables.
The initial stepwise processing was performed on the
subset of 1032 of the 1715 randomized patients who had
complete data on all 41 candidate variables. Thereafter, at
each stage, analysis was carried out on the larger number
of patients who had complete data just for those predic-
tors already in the model, or, in the case of adding vari-
ables, for those predictors plus each candidate variable
not in the model individually in its own turn. In this way,
the later processing used the maximum possible number
of patients at each stage. The final multivariate model
used data from 1484 patients.
The criterion for statistical significance was the 0.05
probability level. All models, univariate as well as multi-
variate, had terms forced in for randomized study med-
ication so that all analyses were automatically adjusted
for any effects study medication might have had, inde-
pendently of whether those effects attained significance.
All analyses were carried out with the Statistical Anal-
ysis System (SAS), versions 6 or 8 (Cary, NC, USA). In
keeping with the intent-to-treat principle, all randomized
patients were included in all analyses where availability
of data made it possible, regardless of subsequent adher-
ence to coded medication.
RESULTS
The baseline characteristics of the cohort are shown
in Table 1. The average age was 58.9 ± 7.7 years; almost
30% had evidence of prior cardiovascular disease at base-
line. Mean eGFR was 48.1 ± 18.3 mL/min, with a range
of 11.4 mL/min to 155.4 mL/min. Mean 24-hour urinary
albumin:creatinine ratio was 1416.2 ± 1261.1 mg/g, with
range between 16.7 mg/g to 12074.1 mg/g.
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Table 1. Baseline characteristics
Characteristic Cohort (N = 1715)








Duration of diabetes years 14.9 ± 8.5
Ever smoked % 61.6
Total cholesterol mg/dL ± SD 229.0 ± 59.0
Previous cardiovascular diseasea % 29.0
Prior MI % 16.5
Prior HF % 7.5
Prior stroke % 11.6
Systolic BP (mm Hg) ± SD 155.8 ± 18.4
Diastolic BP (mm Hg) ± SD 85.4 ± 10.7
b blocker % 27.1
ACE inhibitor % 10.8
Statin % 26.8
Creatinine mg/dL ± SD 1.7 ± 0.6
eGFR mL/min ± SD 48.1 ± 18.3
Urine albumin:creatinine ratio mg/g ± SD 1416.2 ± 1261.1
aHistory of MI, CHF, stroke, or peripheral vascular disease.
Of the 1715 randomized patients, 518 (30.2%) experi-
enced the CV composite end point. Proportions of the
CV composite experienced as the first event were: 4.1%
for CV death, 5.5% for nonfatal MI, 11.8% for HF, 3.6%
for stroke, 3.4% for unplanned coronary revasculariza-
tion, and 1.8% for unplanned peripheral revasculariza-
tion and/or amputation.
Univariate analysis for predictors
Demographic and clinical risk factors for CV events.
Older age at randomization, longer duration of diabetes
mellitus, and history of CVD were associated with car-
diovascular events (Table 2). Other associations included
history of congestive heart failure, history of myocar-
dial infarction, prior stroke, ever smoking, and history
of angina at baseline. Use of aspirin/antiplatelet agents,
calcium channel blockers, diuretics, and insulin at presen-
tation associated with CV events. Individuals of Hispanic,
Asian, or Pacific Islander background were less likely to
experience CV events than non-Hispanic Caucasians or
blacks.
Physical examination findings of neuropathy and
retinopathy at baseline correlated with increased CV
risk (Table 2). Higher-seated systolic and lower diastolic
blood pressures at baseline appeared predictive for CV
events.
Baseline laboratory characteristics for CV events. With
respect to serum chemistries, individuals who experi-
enced a CV event tended to have lower serum phos-
phorous, calcium, albumin, hemoglobin, and higher LDL
cholesterol and blood urea nitrogen (BUN) at baseline
Table 2. Significant univariate predictors
Relative
risk
Variable estimate 95% CI P value
Demographic
Age years 1.03 1.02–1.04 <0.0001
Other racea 0.65 0.48–0.88 0.005
Duration of diabetes years 1.03 1.02–1.04 <0.0001
History of CVDb 2.45 2.05–2.94 <0.0001
History of angina 1.74 1.41–2.16 <0.0001
History of MI 2.04 1.63–2.54 <0.0001
History of CHF 2.66 2.08–3.40 <0.0001
History of stroke 1.78 1.38–2.31 <0.0001
Smoking (ever) 1.40 1.16–1.69 <0.001
Male gender 1.28 1.06–1.55 0.01
Medications at entry
Aspirin/antiplatelet agents 1.64 1.38–1.96 <0.0001
Calcium channel blockers 1.29 1.08–1.53 0.005
Diuretics 1.40 1.18–1.66 <0.001
Insulin use 1.24 1.04–1.48 0.02
Physical examination parameters
Neuropathy 1.39 1.16–1.67 <0.001
Retinopathy 1.31 1.07–1.61 0.008
Seated DBP mm Hg 0.99 0.98–1.00 0.049
Seated SBP mm Hg 1.01 1.00–1.01 <0.001
Laboratory parameters
Blood urea nitrogen mg/dL 1.01 1.01–1.02 <0.001
Urinary albumin/creatinine ratioc 1.42 1.27–1.58 <0.0001
eGFR mL/min 0.99 0.99–1.00 <0.001
Serum albumin g/dL 0.53 0.44–0.65 <0.0001
Serum calcium mg/dL 0.75 0.61–0.92 0.005
Serum phosphate mg/dL 1.19 1.04–1.36 0.01
LDL cholesterol mg/dL 1.003 1.001–1.005 0.006
Hemoglobin g/dL 0.95 0.90–0.99 0.02
LDL/HDL cholesterol ratio 1.13 1.06–1.21 <0.001
Relative risk estimate is for yes relative to no for categorical predictors, and
for a 1-unit increase for continuous predictors, except as noted.
aHispanic, Asian, or Pacific Islander, or those designated simply as ‘Other.’
bComprises claudication, previous MI, CABG, PTCA, other cardiac revas-
cularization procedure, arterial thromboembolism, TIA, stroke, HF, abdominal
aortic aneurysm, or angina.
cAnalyzed as natural logarithm. Results for are for 1 unit increase in natural
logarithm (corresponding to multiplication of raw urinary albumin:creatinine
ratio by 2.718).
(Table 2). Lower eGFR was associated with CV events.
Baseline serum parameters that did not associate with
CV events were HbA1c, glucose, and HDL cholesterol.
Regarding baseline urinary chemistries, high 24-hour uri-
nary albumin:creatinine excretion ratio was predictive for
CV events.
The proportion of individuals experiencing the CV
composite end point progressively increased with increas-
ing quartiles of baseline urine albumin:creatinine ratio
(Fig. 1A, P < 0.01); similarly, the proportion experienc-
ing CV events progressively increased with decreasing
quartiles of serum albumin (Fig. 1B, P < 0.01).
Multivariate analysis for predictors
The baseline demographic, clinical characteristics, and
laboratory parameters were analyzed simultaneously to
determine which measurements were independent risk
factors of a CV event adjusted for all the others entering
























P for trend < 0.01
17–776 777–1500 1501–2758 2759–12074
(N = 406) (N = 403) (N = 409) (N = 406)
























P for trend < 0.01
1.8–3.6 3.7–3.9 4.0–4.1 4.2–5.1
(N = 484) (N = 447) (N = 298) (N = 337)
Quartiles of serum albumin, g/dL
Fig. 1. Proportion of individuals experiencing the CV composite end
point by quartiles of (A) baseline urinary albumin:creatinine ratio
(mg/g) and (B) baseline serum albumin (g/dL).
the model (Table 3). Eight independent risk factors were
identified and included: older age, male gender, history
of CVD, history of congestive heart failure, longer dura-
tion of diabetes, low serum albumin, and high urine albu-
min:creatinine excretion ratios. Also, relative to white or
black race, those of Hispanic, Asian/Pacific Islander, In-
dian/Pakistani, and all others were significantly less likely
to experience CV events.
CONCLUSION
Compared with the general population, individuals
with diabetic nephropathy and hypertension are at high
risk for adverse CV outcomes; despite blood pressure–
lowering therapy, over 30% of the IDNT cohort experi-
enced at least one CV event. This analysis has identified
baseline patient characteristics, beyond conventional risk
factors, which are predictive for adverse cardiac outcomes
in an already high CV risk population, having both dia-
betic nephropathy and hypertension.
As anticipated, a history of CVD and/or HF identi-
fied a very high-risk group for future events; this can
be explained by the integration of a number of factors.
Having either history at baseline signifies an individual
with complex medical history (hypertension, smoking,
dyslipidemia, insulin use, and CV medications), greater
atherosclerotic burden, underlying cardiac dysfunction,
and more complicated diabetes, all of which are estab-
lished predictors for cardiac events.
Older age and male gender predicted CV events. In-
dependent of age, a longer duration of diabetes at base-
line also was predictive for CV events. Diabetes is associ-
ated with accelerated atherosclerosis; the age-adjusted
relative risk for CV death is three-fold higher among
diabetics than the general population [9]. A longer du-
ration of diabetes reflects prolonged exposure to the hy-
perglycemic state associated with development of both
micro- and macrovascular complications [10]. Baseline
HbA1C and/or blood glucose levels were not associated
with events in our study. Previous studies documenting
association of HbA1C and/or fasting blood glucose levels
to cardiac events, however, did not only rely upon base-
line values, and followed their cohorts serially over time
[11, 12]. Isolated HbA1C and blood glucose levels at base-
line only represent glycemic control for a brief period at
most, and may not appropriately reflect many years of
hyperglycemia exposure.
The degree of albuminuria, assessed by urinary al-
bumin:creatinine ratio, contributed significantly to in-
creased risk; this despite all individuals already having
clinically significant baseline proteinuria (≥900 mg/day).
Every natural log unit increase in urinary albu-
min:creatinine ratio was associated with a 29% increase
in the risk for CV events, the other predictors being as-
sumed fixed. Albuminuria is a powerful predictor for pro-
gression to end-stage renal disease [6, 13]. It not only re-
flects glomerular damage, but is also a sensitive indica-
tor of generalized atherosclerotic-mediated vasculopa-
thy [14] and is considered to be a marker of significant
vascular risk [15–17]. Several retrospective and prospec-
tive studies have consistently demonstrated that wors-
ening albuminuria is paralleled by increasing cardiovas-
cular complications [4, 17]. Albuminuria clusters with a
number of vascular risk factors inclusive of hypertension,
renal dysfunction, dyslipidemia, hyperhomocysteinemia,
and several inflammatory markers [17]; this may also ex-
plain why traditional risk factors such as hypertension and
dyslipidemia lost significance following multivariable
analysis. The precise mechanism by which albuminuria
portends increased CV risk is currently unknown; several
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Table 3. Significant baseline predictors for CV events from multivariate analysis
Categorical Relative riskd Change in predictor
(y/n) or to increase risk by 20%
Predictor continuous v 2 Wald Estimate 95% CI P value (continuous predictors)
Hx of CV diseasea 43.91 2.00 1.63–2.45 <0.0001
Urinary albumin/creatinine ratiob Cont 13.58 1.29 1.13–1.48 0.0002 2.0-fold
Age at entry years Cont 10.58 1.02 1.01–1.04 0.001 8.0 years
Duration of diabetes years Cont 10.28 1.02 1.01–1.03 0.001 9.5 years
Hx of CHF y/n 8.10 1.53 1.14–2.06 0.004
Serum albumin g/dL Cont 6.96 0.70 0.53–0.91 0.008 −0.51 g/dL
Male gender y/n 6.25 1.31 1.06–1.62 0.012
Other racec y/n 5.28 0.68 0.49–0.95 0.022
Relative risk estimate is for yes relative to no for categorical predictors, and for a 1-unit increase for continuous predictors, except as noted.
aComprises claudication, previous MI, CABG, PTCA, other cardiac revascularization procedure, arterial thromboembolism, TIA, stroke, CHF, abdominal aortic
aneurysm, or angina.
bResults are for 1 unit increase in natural logarithm (corresponding to multiplication of raw urinary albumin:creatinine ratio by 2.718).
cOther race denotes Hispanic, Asian, or Pacific Islander, or those designated simply as ‘Other.’
dResults in table are for final model.
derangements in the fibrinolysis and coagulation systems
have been noted, favoring a thrombogenic state [18]. Low
serum albumin was also found to be predictive for events;
this may not only reflect the severity of albuminuria, but
has also been shown to signify excessive catabolism [19].
Low serum albumin levels appear to signify a heightened
state of inflammation, which in itself is a strong predictor
for CV events [20].
In this cohort, although lower baseline eGFR demon-
strated univariate association, it was not an inde-
pendent predictor for CV events. Many studies have
demonstrated significant influence of renal dysfunc-
tion upon adverse cardiovascular outcomes in com-
munity and high-risk cardiac populations. Particular
studies have included analyses involving the Framing-
ham cohort, NHANES I, Atherosclerotic Risk in the
Community (ARIC), Survival and Ventricular Enlarge-
ment (SAVE), Studies of Left Ventricular Dysfunc-
tion (SOLVD), Thrombolysis in Myocardial Infarction
(TIMI), and Valsartan in Acute Myocardial Infarction
(VALIANT) trials [2, 21–23]. In most studies, reduced
renal function, whether measured by eGFR or serum
creatinine, was associated with higher mortality and ad-
verse CV event rates. However, these studies consisted of
mixed populations of chronic kidney disease (CKD) and
normal renal function patients; the prevalence of CKD
and/or diabetes in these studies was relatively low, yet
these individuals were found to be at high risk for CV
events. These studies did not examine the influence of
albuminuria. Among diabetics with nephropathy, the de-
gree of albuminuria has been shown to demonstrate an
inverse relationship with eGFR [24]. In the context of
diabetic nephropathy, in which CKD and high risk for
CV events is already established, low eGFR and/or high
serum creatinine may already be accounted for by the de-
gree of albuminuria, which in itself is a surrogate of renal
dysfunction severity [25].
Lower hemoglobin concentrations conferred increased
risk in the univariate analysis; however, it was not an
independent predictor for CV events. Chronic anemia
has been demonstrated to be an independent risk factor
for adverse CV outcomes, particularly in patients with
kidney disease and/or heart failure [26, 27]. Anemia is
also an independent predictor for renal disease progres-
sion [28] because it reflects progressive erythropoietin
deficiency and the negative influence of increasing ure-
mic factors upon erythropoiesis [29]. The mechanism for
the association between anemia and CV events is un-
clear; in addition to reduced oxygen supply to already
ischemic tissue, it is postulated that the presence of ane-
mia may also be signifying systemic inflammatory activ-
ity [30]. Based on such hypotheses, the loss of its signif-
icance following multivariable analysis may have been
accounted for by other proinflammatory factors such as
albuminuria.
Individuals of Hispanic, Asian, or Pacific Islander ex-
traction, or those classed as ‘other’ were less likely to
experience CV events. This is in contrast to what has
been reported in the literature. A number of studies in-
volving registries have demonstrated that individuals of
non-Caucasian extraction are at higher risk for both
cardiovascular and renal disease; these same pop-
ulations also appear to be experiencing a rising
prevalence and incidence of type 2 diabetes mellitus
[31]. Genetic predisposition, socioeconomic status, re-
duced awareness, and cultural factors play important
roles.
Given so many potential risk factors were analyzed
raises the probability of false positives (i.e., of incorrectly
identifying one or more covariates as predictors of risk).
In addition, given the IDNT study was not specifically de-
signed for risk factor analysis, chances for false negatives
(i.e., of failing to recognize one or more legitimate predic-
tors) may be high also; of note, we did have not complete
electrocardiographic and/or chest x-ray data, which may
have altered our model.
Patients with overt diabetic nephropathy and hyper-
tension are at significant risk for adverse cardiac events.
Among this cohort, individuals at higher risk for CV
events are more likely to be male, older in age, have a
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longer duration of diabetes, prior history of cardiovas-
cular disease and/or CHF, marked albuminuria, and hy-
poalbuminemia. In addition to traditional coronary risk
factors, the degree of albuminuria and low serum albumin
levels are important independent prognostic variables for
cardiovascular events in this high-risk cohort.
APPENDIX
The following 41 potential predictors were used in the CV events
analysis:
Continuous variables: age (years), serum albumin (g/dL), body mass
index, BUN, serum calcium (mg/dL), LDL (mg/dL), HDL (mg/dL),
LDL:HDL ratio, duration of diabetes (years), blood glucose whether
or not fasted, hemoglobin, hemoglobin A1c, serum potassium (mg/dL),
MDRD estimate of GFR (mL/min), serum sodium (mg/dL), serum
phosphorus (mg/dL), 24-hr urinary albumin:creatinine ratio, seated
diastolic blood pressure (mm Hg), seated systolic blood pressure
(mm Hg).
Categorical variables (yes/no): male gender, black race, other race,
family history of diabetes, family history of hypertension, history of
neuropathy, history of retinopathy, smoking at entry, history of ever
smoking, history of CV disease, history of MI, history of CHF, history
of stroke, history of angina, use at entry of ACEi, aspirin/antiplatelet
drugs, b-blockers, calcium channel blockers, diuretics, insulin, met-
formin/phenformin, sulfonylureas.
Note: Serum calcium was adjusted for serum albumin. Natural log of
24-hr urinary albumin:creatinine ratio was used. Other race denotes
Hispanic, Asian, and/or Pacific Islander, or those classed simply as
‘other’.
Reprint requests to Dr. Marc A. Pfeffer, Cardiovascular Division,
Brigham & Women’s Hospital, 75 Francis Street, Boston, MA 02115.
E-mail: mpfeffer@rics.bwh.harvard.edu
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